

# Maximilian Merz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1683439/publications.pdf>

Version: 2024-02-01

57  
papers

792  
citations

471061

17  
h-index

580395

25  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. <i>Nature Communications</i> , 2022, 13, 807.	5.8	29
2	Multiples Myelom: Daratumumab als Standard in der Erstlinientherapie bei nicht-transplantablen, neudiagnostizierten Myelompatienten. <i>Karger Kompass Onkologie</i> , 2022, 9, 18-19.	0.0	0
3	Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage. <i>British Journal of Haematology</i> , 2022, 199, 65-75.	1.2	8
4	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822.	3.3	7
5	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2021, 13, 143-154.	1.0	9
6	Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 245.e1-245.e8.	0.6	4
7	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. <i>Cancers</i> , 2021, 13, 961.	1.7	8
8	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. <i>Leukemia</i> , 2021, 35, 3007-3011.	3.3	4
9	Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. <i>Cancers</i> , 2021, 13, 5996.	1.7	8
10	Diffusion-Weighted MRI – The Way Forward for MRI in Myeloma?. <i>Hemato</i> , 2021, 2, 672-679.	0.2	0
11	Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. <i>Leukemia</i> , 2020, 34, 1192-1196.	3.3	26
12	Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. <i>Cancers</i> , 2020, 12, 2537.	1.7	7
13	Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. <i>Leukemia and Lymphoma</i> , 2020, 61, 2365-2374.	0.6	4
14	Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. <i>Cancers</i> , 2020, 12, 1335.	1.7	6
15	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.	3.3	47
16	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1709-1725.	0.8	12
17	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898.	1.1	6
18	EASIX for prediction of survival in lower-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2019, 9, 85.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 71.	2.8	7
20	Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 13.	2.8	6
21	Quantitative dynamic <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. <i>Haematologica</i> , 2019, 104, e420-e423.	1.7	12
22	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
23	Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. <i>Haematologica</i> , 2018, 103, e162-e164.	1.7	5
24	Minimal residual disease in multiple myeloma: use of magnetic resonance imaging. <i>Seminars in Hematology</i> , 2018, 55, 19-21.	1.8	18
25	Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients. <i>Hematological Oncology</i> , 2018, 36, 232-237.	0.8	20
26	Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2018, 2, 1-9.	2.5	25
27	Cytogenetic intracлонаl heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	2.5	33
28	Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 2717-2719.	3.3	10
29	Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients. <i>BMC Cancer</i> , 2018, 18, 820.	1.1	18
30	Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 25254-25264.	0.8	15
31	Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century. <i>Haematologica</i> , 2017, 102, e229-e232.	1.7	8
32	Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. <i>Annals of Hematology</i> , 2017, 96, 987-993.	0.8	17
33	Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. <i>Haematologica</i> , 2017, 102, 1432-1438.	1.7	14
34	Genetic Susceptibility to Bortezomib-Induced Peripheral Neuropathy: Replication of the Reported Candidate Susceptibility Loci. <i>Neurochemical Research</i> , 2017, 42, 925-931.	1.6	15
35	Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trial. <i>Oncotarget</i> , 2017, 8, 68460-68471.	0.8	14
36	Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 174, 127-135.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	1.7	14
38	Diagnostic and therapeutic approaches to multiple myeloma patients: â€œReal-worldâ€™ data from representative multicentre treatment surveys in Germany between 2008 and 2011. <i>Oncology Letters</i> , 2016, 12, 5043-5051.	0.8	10
39	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2016, 91, E473-E477.	2.0	27
40	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApSE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <i>BMC Cancer</i> , 2016, 16, 290.	1.1	5
41	Survival of elderly patients with multiple myelomaâ€™Effect of upfront autologous stem cell transplantation. <i>European Journal of Cancer</i> , 2016, 62, 1-8.	1.3	27
42	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. <i>European Radiology</i> , 2016, 26, 3939-3948.	2.3	27
43	Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 247-251.	1.2	1
44	Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. <i>European Radiology</i> , 2016, 26, 1404-1411.	2.3	28
45	Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4415-4415.	0.6	1
46	Extramedullary relapse after accidental head injury in a patient with multiple myeloma. <i>Annals of Hematology</i> , 2015, 94, 351-353.	0.8	0
47	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 106-112.	3.2	38
48	Diffusion-weighted imaging and dynamic contrast-enhanced MRI of experimental breast cancer bone metastases â€™ A correlation study with histology. <i>European Journal of Radiology</i> , 2015, 84, 623-630.	1.2	7
49	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. <i>Haematologica</i> , 2015, 100, 818-825.	1.7	45
50	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969.	1.7	62
51	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4233-4233.	0.6	2
52	Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways. <i>Blood</i> , 2015, 126, 723-723.	0.6	0
53	Assessing Treatment Response of Osteolytic Lesions by Manual Volumetry, Automatic Segmentation, and RECIST in Experimental Bone Metastases. <i>Academic Radiology</i> , 2014, 21, 1177-1184.	1.3	8
54	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma â€™ Subgroup Analysis from the GMMG-MM5 Trial. <i>Blood</i> , 2014, 124, 3475-3475.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Impact of Radiation Therapy on Stem Cell Harvest in Multiple Myeloma. Blood, 2014, 124, 5822-5822.	0.6	1
56	GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance â€œ Final Analysis On Induction Therapy. Blood, 2013, 122, 3369-3369.	0.6	3
57	Longitudinal whole body MRI (wbMRI) in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8590-8590.	0.8	1